Major support from Cancer Council NSW
Cancer Council NSW has announced a grant of $2.25 million over the next five years to support the work of Professor Roger Reddel's laboratory team.
The grant will fund their work on Alternative Lengthening of Telomeres (ALT), a cellular process that 10-15% of all cancers – in children and adults – depend on for their continuing growth. ALT is critically important for cancer cells because it allows them to prevent the shortening of chromosome ends (i.e., telomeres) that would otherwise accompany their proliferation.
Some of the tumour types that depend on ALT are currently very difficult to treat, and the outcome for patients who have these cancers is very poor. The CMRI group has made major advances in understanding ALT, and is currently developing technologies that will make it possible to start searching soon for drugs that block ALT.
Cancer Council NSW has provided major support for this work over many years, which has been a major factor in the success of this long-term, highly innovative work.
CMRI is delighted that Cancer Council NSW has decided to continue their investment in this research, in the expectation that it will benefit large numbers of cancer patients.